Most people who come to us asking about ketamine treatment are focused, understandably, on what happens in the brain. They’ve read about NMDA receptors, about BDNF, about how ketamine seems to rapidly restore synaptic connections that depression has worn down. That’s all real, and we talk about it often. But there’s a quieter part of this story that research has been filling in over the past several years: what happens below the neck.
The gut-brain axis—a term describing the bidirectional communication network between the gastrointestinal system and the central nervous system—is increasingly recognized as a meaningful contributor to mental health. And ketamine, it turns out, appears to engage this system in measurable ways. We find this line of research genuinely interesting, not because it changes how we approach treatment day-to-day, but because it helps explain why the same medication can produce effects that touch mood, inflammation, pain, and cognition all at once.
What the Gut-Brain Axis Actually Is
The phrase gets used loosely, so it’s worth being precise. The gut-brain axis is not a single pathway. It’s a web of communication channels that includes the vagus nerve (which runs directly from the brainstem to the gut), the enteric nervous system (the network of neurons embedded in the gastrointestinal wall), the hypothalamic-pituitary-adrenal (HPA) axis, and immune signaling molecules that circulate between the two systems.
Living inside this system—mostly in the large intestine—is the gut microbiome: the community of trillions of bacteria, fungi, and other microorganisms that has co-evolved with human biology. These microbes are not passive passengers. They produce neurotransmitter precursors like tryptophan (a building block of serotonin), synthesize short-chain fatty acids (SCFAs) that influence inflammation and gut barrier integrity, and communicate with immune cells that subsequently traffic to the brain.
A 2025 review in Frontiers in Immunology mapped this bidirectional communication in depression specifically, showing that disruptions in gut bacterial populations can drive neuroinflammation upward into the brain, while chronic psychological stress signals back down through cortisol and autonomic pathways to alter microbial composition. The relationship is genuinely two-directional, which makes the gut-brain axis both a plausible contributor to depression and a plausible target for treatment.
How Ketamine Engages the Gut-Brain Axis
A 2026 review in Molecular Psychiatry identified three primary mechanisms through which ketamine appears to engage the gut-brain axis: altering microbial composition, regulating the production of microbial metabolites, and controlling immune cell trafficking from the intestines to the brain. These aren’t speculative; each has evidence behind it, even if the picture is still being filled in.
Earlier groundwork came from a 2018 study in BMC Microbiology, which showed that ketamine’s interactions with gut microbiota in animal models were relevant to both its antidepressant and anti-inflammatory properties—suggesting the two effects might share a common mechanism at the gut level, rather than running on entirely separate tracks.
A 2022 review in Neuropharmacology by Yang et al. drew explicit connections between ketamine’s antidepressant effects and modifications in gut microbiome composition and metabolite production. In other words, changes in what’s living in the gut, and what those organisms are producing, appear to be part of how ketamine works—not just a downstream side effect.
The Bacteria That Seem to Matter
Research has started to identify specific microbial taxa that appear to facilitate ketamine’s therapeutic action. Two that come up in the literature are Actinobacteria and Coriobacteria—bacterial families whose relative abundance shifts following ketamine treatment and whose metabolic activity is thought to influence the gut-brain communication pathways described above.
What these bacteria are doing, mechanistically, is an active area of investigation. Coriobacteria in particular are known to be involved in bile acid metabolism and the conversion of dietary compounds into bioactive forms. Their interaction with ketamine treatment may influence how efficiently the gut produces certain neurochemical precursors and signaling molecules. We’re in relatively early days on specifics here, but the directional findings are consistent across several independent studies.
Short-Chain Fatty Acids and Gut Barrier Health
One of the more concrete findings from this line of research involves short-chain fatty acids (SCFAs)—compounds produced when gut bacteria ferment dietary fiber. The three most studied are butyrate, propionate, and acetate. They are not trivial byproducts. SCFAs help maintain the integrity of the gut epithelial barrier (the single-cell-thick lining that keeps bacterial products from leaking into the bloodstream), modulate immune cell function, and can cross the blood-brain barrier to influence neuroinflammation directly.
Research indicates that ketamine treatment is associated with increased SCFA production, which in turn supports a healthier distribution of gut bacteria. This matters because people with depression and treatment-resistant depression frequently show evidence of gut barrier disruption and reduced SCFA-producing bacterial populations. The idea that ketamine might partly restore this balance—rather than simply acting on the brain in isolation—is one of the more interesting threads in current research.
This connects to what we discuss in our article on ketamine and neuroinflammation: the gut’s immune signaling is one of the channels through which peripheral inflammation reaches the brain. If ketamine is reducing that upstream signal in part by improving gut barrier integrity and SCFA production, then the anti-inflammatory effects observed in the brain may have roots that extend considerably further south than the NMDA receptor.
Esketamine, Amino Acids, and Depressive Behavior
A 2025 study in BMC Microbiology looked specifically at esketamine—the S-enantiomer form of ketamine used in the nasal spray Spravato—and found that it alleviates depressive-like behavior through modulation of the microbiota-gut-brain axis and amino acid metabolism. This is worth noting because esketamine is a somewhat different molecule than racemic IV ketamine, and yet gut-brain axis engagement appears in both. Amino acid metabolism matters here because several key amino acids—tryptophan, glutamate, GABA precursors—are produced or processed by gut bacteria and feed directly into neurotransmitter synthesis.
If the gut microbiome is producing the right amino acid environment, the brain has better raw material to work with. If it isn’t, that deficit can compound the neurochemical imbalances that contribute to depression. Ketamine’s apparent ability to shift microbial composition toward more favorable amino acid metabolism is one reason researchers are taking the gut-brain axis angle seriously rather than treating it as a peripheral curiosity.
What This Means in Practice
We want to be honest about the limits of where this research currently sits. Most of the mechanistic work has been done in animal models, with human studies catching up but not yet fully arrived. The clinical picture—how much of ketamine’s antidepressant effect in humans is attributable to gut-brain axis pathways versus direct CNS action versus the BDNF-driven neuroplasticity we discuss in our BDNF article—isn’t resolved. These are likely additive and overlapping mechanisms, not competing ones.
What this research does suggest is that ketamine’s reach is broader than a single receptor. For patients who come in having tried multiple antidepressants without success, understanding that ketamine operates through several distinct biological channels—including ones that conventional antidepressants don’t touch—helps explain why it sometimes works when other things haven’t. It’s not acting on a single point of failure. It’s engaging the system at multiple levels simultaneously.
For a fuller picture of ketamine’s primary mechanism of action, we recommend reading our article on how ketamine works. The gut-brain axis findings make more sense in context of the broader mechanistic framework.
There is also the question of what patients can do to support their gut health alongside ketamine treatment. Honestly, there’s no established clinical protocol yet. The research isn’t at a point where we can say “take this probiotic strain at this dose and you’ll get better results.” What we do know is that the general foundations of gut health—dietary fiber, limited processed food, adequate sleep, reduced chronic stress—are the same foundations that support brain health broadly. If you’re preparing for a course of ketamine treatment and you have gut health concerns, bring them up with us. We’re glad to think through what might be relevant for your specific situation.
Research suggests ketamine engages the microbiota-gut-brain axis through at least three distinct mechanisms—altering microbial composition, regulating metabolite production, and controlling immune trafficking between intestine and brain. — Molecular Psychiatry, 2026
The gut-brain axis research also connects to a broader point about why ketamine treatment works best when it’s embedded in a thoughtful clinical process rather than treated as a standalone infusion. The biology is complex and multi-layered. Preparation, integration, and attention to overall health context matter. That’s how we approach things at Music City Ketamine—not as a procedure to administer, but as a treatment to support.